Technical Analysis for PDSB - PDS Biotechnology Corporation

Grade Last Price % Change Price Change
F 3.20 0.31% 0.01
PDSB closed up 0.31 percent on Friday, November 1, 2024, on 81 percent of normal volume. It ran into resistance at its 50 day moving average.
Earnings due: Nov 12
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
20 DMA Resistance Bearish 0.31%
50 DMA Resistance Bearish 0.31%
Down 3 Days in a Row Weakness 0.31%
20 DMA Resistance Bearish -0.47%
50 DMA Resistance Bearish -0.47%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.47%

   Recent Intraday Alerts

Alert Time
50 DMA Resistance about 18 hours ago
20 DMA Resistance about 18 hours ago
Rose Above Previous Day's High about 20 hours ago
Up 5% about 20 hours ago
Up 3% about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

PDS Biotechnology Corporation Description

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Oncology Cancer Immunotherapy Breast Cancer Immunotherapies Prostate Cancer Melanoma Treatment Of Breast Cancer Lipid Oncolytics Biotech Head And Neck Cancer Cervical Cancer Anal Cancer

Is PDSB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.85
52 Week Low 2.53
Average Volume 311,083
200-Day Moving Average 3.76
50-Day Moving Average 3.25
20-Day Moving Average 3.27
10-Day Moving Average 3.19
Average True Range 0.24
RSI (14) 47.37
ADX 13.0
+DI 18.91
-DI 15.81
Chandelier Exit (Long, 3 ATRs) 3.58
Chandelier Exit (Short, 3 ATRs) 3.73
Upper Bollinger Bands 3.58
Lower Bollinger Band 2.95
Percent B (%b) 0.4
BandWidth 19.17
MACD Line -0.04
MACD Signal Line -0.03
MACD Histogram -0.007
Fundamentals Value
Market Cap 99.54 Million
Num Shares 31.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -1.87
Price-to-Sales 0.00
Price-to-Book 6.77
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.50
Resistance 3 (R3) 3.52 3.43 3.45
Resistance 2 (R2) 3.43 3.36 3.43 3.43
Resistance 1 (R1) 3.32 3.31 3.38 3.30 3.42
Pivot Point 3.23 3.23 3.26 3.23 3.23
Support 1 (S1) 3.12 3.16 3.18 3.10 2.98
Support 2 (S2) 3.03 3.11 3.03 2.97
Support 3 (S3) 2.92 3.03 2.95
Support 4 (S4) 2.90